Molina Healthcare (MOH) Q2 2025 Earnings
Reported Jul 23, 2025 at 4:17 PM ET · SEC Source
Q2 25 EPS
$5.48
MISS 0.93%
Est. $5.53
Q2 25 Revenue
$11.43B
BEAT +4.44%
Est. $10.94B
vs S&P Since Q2 25
+10.0%
BEATING MARKET
MOH +29.0% vs S&P +19.0%
Market Reaction
Did MOH Beat Earnings? Q2 2025 Results
Molina Healthcare delivered a mixed second quarter for 2025, posting strong revenue growth that masked a meaningful earnings shortfall and prompted the company to lower its full-year profit outlook for the second time this year. Revenue climbed 15.7%… Read more Molina Healthcare delivered a mixed second quarter for 2025, posting strong revenue growth that masked a meaningful earnings shortfall and prompted the company to lower its full-year profit outlook for the second time this year. Revenue climbed 15.7% year over year to $11.43 billion, clearing the $10.94 billion consensus by 4.44%, as new contract wins, acquisitions, and rate increases pushed premium revenue to $10.87 billion. But profitability told a harder story: adjusted EPS of $5.48 came in just below the $5.53 consensus estimate, weighed down by a deteriorating consolidated medical care ratio that widened to 90.4% from 88.6% a year ago, as utilization pressure spread across all three segments. The Marketplace segment was the most acute pressure point, with its MCR jumping to 85.4% from 71.6%, partly due to the ConnectiCare acquisition and prior-year member reconciliations. Analysts have noted the pattern of repeated guidance reductions, and Molina's revised full-year adjusted EPS floor of $19.00, down sharply from an initial $24.50, reinforced those concerns even as premium revenue guidance held firm at approximately $42 billion.
Key Takeaways
- • Premium revenue growth of 15% year over year driven by new contract wins, acquisitions, footprint growth, and rate increases
- • Membership increased by 167,000 to approximately 5.7 million year over year
- • Marketplace membership nearly doubled to 690,000 from 386,000 year over year
- • G&A ratio improved to 6.2% (6.1% adjusted) reflecting one-time items and operating discipline
- • Consolidated MCR deteriorated to 90.4% from 88.6% due to elevated medical cost utilization
MOH YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
MOH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our second quarter results and revised full year outlook reflect a challenging medical cost trend environment.”
— Joseph Zubretsky, Q2 2025 Earnings Press Release
MOH Earnings Trends
MOH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
MOH EPS Trend
Earnings per share: estimate vs actual
MOH Revenue Trend
Quarterly revenue: estimate vs actual
MOH Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $0.33 | $-2.75 | -921.63% | $11.38B | +4.31% |
| FY Full Year | $13.93 | $11.03 | -20.80% | $45.43B | +1.02% |
| Q3 25 MISS | $3.89 | $1.84 | -52.73% | $11.48B | +4.49% |
| Q2 25 MISS | $5.53 | $5.48 | -0.93% | $11.43B | +4.44% |
| Q1 25 BEAT | $5.96 | $6.08 | +2.05% | $11.15B | +3.08% |